Epcoritamab, a CD3 x CD20 Bispecific Antibody, Plus R-CHOP in Untreated High-Risk DLBCL: Updated Analysis of Phase I/II EPCORE NHL-2 Trial

Source: 2022 ASCO Annual Meeting*
Download Slideset
June 3-7, 2022; Chicago, Illinois
In this updated analysis of the patient cohort with newly diagnosed high-risk DLBCL, epcoritamab SC combined with R-CHOP had a manageable safety profile and yielded an ORR of 100% and a CMR of 77%.
Format: Microsoft PowerPoint (.ppt)
File Size: 131 KB
Released: June 16, 2022

Acknowledgements

Provided by Clinical Care Options, LLC
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AbbVie
AstraZeneca
Gilead Sciences, Inc.
Merck Sharp & Dohme Corp.
Novartis Pharmaceuticals Corporation
Seagen

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings